Neuromodulation and the frontiers of bioelectronic therapy

Wednesday, September 30, 2020 8:15 PM to 9:00 PM · 45 min. (UTC)

Information

Advances at the intersection of neuroscience and technology are about to radically transform how doctors monitor and treat brain-related conditions ranging from chronic pain and PTSD to epilepsy and depression. In this SynBioBeta session, Mayfield partner Ursheet Parikh talks with leaders in the field about emerging approaches, potential applications, and the industrial ecosystem of this fast-emerging field. We’ll explore:

The historical development of neuromodulation and how that has shaped the field today

Recent key advances that are making neuromodulation a more tractable and scalable therapeutic option

Hardware, software, and interface trends that are reshaping the patient experience

The technological and operational barriers of going from product concept to clinical development to market launch and commercialization

A vision for the future of bioelectronic medicine

MayfieldMayfield is a global venture capital firm with $2.5 billion under management. The Firm has been championing people for more than 50 years. Since its founding in 1969, the Firm has invested in more than 500 companies resulting in 117 IPOs and more than 200 mergers or acquisitions. Some recent successes include CloudSimple, Elastica, Grove Collaborative, HashiCorp, Lyft, Mammoth Biosciences, Marketo, Moat, Outreach, ServiceMax and SolarCity 

Registered attendees

AH
Amy Heintz
Tech FellowBattelle
David Borton
David Borton
Assistant ProfessorBrown University
ES
Ellen Simmons
Senior EngineerCambridge Consultants

Join the event!

See all the content and easy-to-use features by logging in or registering!